Industry Insights: Healthcare
This round of #healthcare insights highlights three important developments that promise to better the future of rare disease diagnosis, regulation and education.
A newly proposed pathway for ultra-rare therapies
The US Food and Drug Administration (FDA) has issued a framework on a new approval pathway for highly targeted, individualised genome and RNA therapies. In rare diseases, patient populations are too small to support traditional randomised controlled trials. This is why the agency proposed a so-called Plausible Mechanism Framework. Under this approach, sponsors may generate evidence of safety and effectiveness through a series of guided actions. Eligibility requires clearly defining the causal abnormality and showing that the therapy addresses the cause of a biological pathway. This framework aims to speed up access to life-saving treatments for patients who cannot afford to wait for conventional trials.
Operationalising rare disease knowledge at the point of care
Intelligent Medical Objects (IMO) Health has recently announced the integration of Mondo rare disease ontology into everyday clinical work with the goal of extending access to electronic health records. Nearly 5,000 new rare disease diagnoses and more than 25,000 updated clinical terms are now mapped to Mondo. According to Dr. Melissa Haendel, one of the creators and curators of the Mondo ontology, operationalisation allows clinicians to document conditions using familiar terminology. This integration ultimately promises to improve the identification of patients with rare diseases.
Closing rare disease education gaps through CME
The National Organization for Rare Disorders (NORD) has launched the ‘Earn Your Stripes’ Rare Disease CME Challenge, running from 23 February to 31 March. The initiative aims to encourage clinicians, particularly in primary care and pediatrics, to complete continuous medical education (CME) programmes focused on early recognition, clinical guidelines and care coordination. Delayed diagnosis of rare diseases remains common, often spanning years and multiple specialists. Participation in CME programmes can thus help clinicians stay updated and provide answers for patients and families.
For more industry insights visit elion.nz/insights/
Want to get in touch? Contact us today at https://elion.nz/get-in-touch/
